We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go: Extended investment: £10,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go: Expired investment: Withheld
Founded by entrepreneurs, Oliver Hutley (COO) and Rory Chichester (CEO), TECS Group is an expert provider of technology. TECS Group delivers non-discretionary critical services, such as Electrical Testing and Treatment, Gas Safety, and Fire Safety, on behalf of customers. These services are covered by strict legislation & regulation. Following a constant period of investment into developing a scalable and a solid operating platform, the TECS Group is embarking on its subsequent stage of growth. With the proceeds, the company will deliver and successfully implement its technology strategy, successfully drive for organic sales, increase the national coverage, and continue its final program.
days to go: Expired investment: £96,770
Brompton's bicycle hire allows people to hire folding bicycles from hiring stations. The hiring stations (docks) are sold to partners. The company have already sold 44 docks to partners. They are looking for investment to prepare the business for international expansion. The funding will used to increase the size of their network by placing more docks in strategic locations.  Their service will also be developed with the funds, working on their customer service and developing their skills.
days to go: Expired investment: £380,000
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph